Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial
Source: View publication →
In patients with completely resected WHO grade 2 atypical meningioma, early adjuvant radiotherapy significantly reduces the risk of tumor recurrence and improves 5-year disease-free survival compared to observation alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ROAM/EORTC-1308 trial provides the first robust, randomized Phase 3 evidence demonstrating that early adjuvant radiotherapy significantly reduces the recurrence of completely resected atypical meningiomas. This landmark finding resolves years of clinical uncertainty and establishes early postoperative radiotherapy as an evidence-based standard of care, which is expected to prompt updates to national and international neuro-oncology guidelines.
Historical Context
Meningiomas are the most common primary brain tumors in adults. Atypical (WHO grade 2) meningiomas comprise approximately a quarter of all meningiomas and exhibit an aggressive clinical course with a high risk of recurrence even after gross total resection. Prior to this trial, the neuro-oncology community was divided on the optimal postoperative management strategy: some advocated for immediate adjuvant radiotherapy to prevent relapse, while others preferred a 'watch and wait' observation approach to avoid potential radiation toxicity, reserving radiotherapy as a salvage treatment. The ROAM/EORTC-1308 trial was designed to definitively settle this longstanding clinical dilemma.
Guided Discussion
High-yield insights from every perspective
What specific histological criteria distinguish a WHO grade 2 atypical meningioma from a grade 1 benign meningioma, and why does this grading biologically necessitate evaluating adjuvant therapies like radiotherapy?
Key Response
WHO grade 2 meningiomas are defined by increased mitotic activity (4-19 mitoses per 10 high-power fields), brain invasion, or the presence of at least three specific atypical features such as spontaneous necrosis, sheet-like growth, macronucleoli, small cells, or hypercellularity. These features indicate a more aggressive, rapidly dividing tumor biology with a significantly higher propensity for local recurrence even after surgical removal, forming the clinical rationale for the ROAM trial's investigation of early adjuvant radiotherapy.
Based on the ROAM trial results, how should you counsel a patient who has just undergone a complete (Simpson grade 1) resection of a WHO grade 2 meningioma regarding the choice between immediate adjuvant radiotherapy and observation?
Key Response
The trial demonstrates that early adjuvant radiotherapy significantly reduces recurrence risk and improves 5-year disease-free survival compared to observation alone, even after a macroscopic complete resection. Counseling must shift from the traditional 'watch and wait' approach to actively discussing radiotherapy as an effective tool for local control, while balancing this oncologic benefit against the potential risks of radiation toxicity, such as fatigue, alopecia, and long-term neurocognitive effects.
How does the inherent biological heterogeneity within the 'completely resected' (Simpson grade 1-3) cohort of WHO grade 2 meningiomas impact the absolute benefit of adjuvant radiotherapy, and should emerging molecular markers influence this decision?
Key Response
Simpson grades 1 through 3 are considered 'complete' resections, yet Simpson 3 leaves the dura intact but coagulated, carrying a higher baseline recurrence risk than a Simpson 1 resection. Fellows must critically evaluate if the disease-free survival benefit seen in ROAM is driven predominantly by the Simpson 3 subgroup. Furthermore, integrating molecular profiling, such as TERT promoter mutations or distinct DNA methylation classes, may soon supersede Simpson grading and histology alone in predicting which tumors truly require immediate radiation.
While the ROAM trial establishes a disease-free survival benefit for adjuvant radiotherapy in completely resected grade 2 meningiomas, how do you incorporate patient-specific variables like age, baseline cognitive function, and tumor location to justify active surveillance in clinical practice?
Key Response
As an attending, clinical decision-making extends beyond trial endpoints to overall patient quality of life. For an elderly patient or a highly functioning professional with a completely resected tumor near critical cognitive structures (e.g., dominant frontal lobe), the delayed neurocognitive decline and radiation necrosis risks associated with fractionated cranial irradiation might outweigh the risk of an asymptomatic, salvageable local recurrence. The trial data must be tailored via shared decision-making rather than applied rigidly.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In an open-label trial design like ROAM/EORTC-1308, what methodological biases are introduced when evaluating secondary endpoints such as neurocognitive outcomes and quality of life, and what statistical methods are required to mitigate these biases?
Key Response
Open-label trials evaluating interventions with known subjective side effects (like radiotherapy) are highly susceptible to performance and detection biases, particularly the nocebo effect, where patients expecting radiation fatigue or cognitive decline report worse outcomes. A rigorous critique would evaluate the use of mixed-effects modeling to handle longitudinal patient-reported outcomes, techniques for addressing non-ignorable missing data due to toxicity, and the necessity of a blinded independent central review committee to ensure the primary endpoint of disease-free survival is not biased by investigator knowledge of the treatment arm.
When evaluating the ROAM/EORTC-1308 manuscript for publication, what scrutiny should be applied to the standardization and central radiological verification of 'complete resection' prior to randomization, given its potential to confound the primary endpoint?
Key Response
The inclusion criteria mandate a 'completely resected' tumor. If postoperative baseline MRIs were only evaluated locally without rigorous, standardized central review, microscopic or small macroscopic residual disease might have been missed. If the radiotherapy arm contained patients with unrecognized residual disease (effectively a Simpson 4 resection), the radiation might appear falsely beneficial by treating existing disease rather than genuinely preventing de novo recurrence, posing a major threat to the study's internal validity.
Given the historical clinical equipoise reflected in previous NCCN and EANO guidelines—which listed both observation and radiotherapy as valid options for completely resected WHO grade 2 meningiomas—how should the ROAM/EORTC-1308 phase 3 data alter the strength and level of recommendation for adjuvant radiotherapy?
Key Response
Previous guidelines lacked definitive phase 3 data, resulting in a weak or consensus-based recommendation where observation was often favored to spare toxicity. The ROAM trial provides Level 1 evidence demonstrating a clear disease-free survival benefit for radiotherapy. Guideline committees must now deliberate whether to elevate early adjuvant radiotherapy to a Category 1 recommendation as the new standard of care, while carefully defining specific clinical or molecular subgroups where active surveillance remains an acceptable, evidence-based alternative.
Clinical Landscape
Noteworthy Related Trials
EORTC 22845 Trial
Tested
Early adjuvant radiotherapy (54 Gy)
Population
Adult patients with WHO grade 2 low-grade glioma
Comparator
Delayed radiotherapy at the time of tumor progression
Endpoint
Overall survival (OS)
RTOG 0539 Trial
Tested
Risk-adaptive radiotherapy (54 Gy for intermediate risk)
Population
Patients with newly diagnosed or recurrent WHO grade 1-3 meningioma
Comparator
Observation (for low-risk cohort)
Endpoint
3-year progression-free survival (PFS)
EORTC 2 -26042 Trial
Tested
High-dose adjuvant radiotherapy (60 Gy)
Population
Patients with completely resected WHO grade 2 or 3 meningioma
Comparator
None (Single-arm phase 2 trial)
Endpoint
Progression-free survival (PFS)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis